You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》強生(JNJ.US)上季多賺1.7倍 料今年新冠疫苗銷售急升
阿思達克 01-26 09:17
強生(JNJ.US)第四季盈利增長1.7倍至47.36億美元,收入增長10.4%至248億美元,低於分析師預期的252.9億美元,因爲癌症藥物Imbruvica及治療克隆氏症藥物Stelara等主要收入遜色。 季內醫療設備部門收入爲68.6億美元,低於市場預期的69.8億美元,因爲疫情爆發導致醫院再次推遲非緊急外科手術。 去年強生新冠疫苗銷售額爲23.9億美元,不及公司目標的25億美元,但預計今年新冠疫苗銷售額將增長46%至35億美元,總收入預計將介乎989億至1,004億美元,高於市場預期的977.9億美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account